decemb
outbreak
pneumonia
unknown
etiolog
occur
wuhan
hubei
provinc
china
januari
chines
center
diseas
control
prevent
cdc
isol
novel
coronaviru
throat
swab
sampl
patient
identifi
etiolog
agent
cluster
pneumonia
world
health
organ
name
viru
relat
diseas
coronaviru
studi
group
intern
committe
taxonomi
virus
propos
new
viru
design
sever
acut
respiratori
syndrom
coronaviru
sinc
first
report
case
wuhan
outbreak
follow
exponenti
growth
rapidli
spread
across
china
lead
emerg
committe
declar
global
health
emerg
januari
epidem
extend
mani
countri
across
contin
recogn
pandem
world
health
organ
march
global
case
march
exceed
china
itali
countri
affect
spread
infect
italian
epidemiolog
data
updat
march
show
critic
situat
total
confirm
infect
peopl
recov
deceas
therefor
time
written
itali
nation
death
due
worldwid
reason
may
relat
differ
factor
time
modal
confin
older
median
age
rate
smoke
pollut
moreov
report
death
system
includ
case
deceas
coronaviru
rather
coronaviru
clinic
chart
review
ongo
detect
causal
lack
precis
number
asymptomat
subject
also
prevent
possibl
calcul
true
infect
fatal
rate
strictli
depend
extent
swab
test
whole
gener
popul
asymptomat
infect
fact
describ
exact
preval
still
unknown
order
estim
proport
asymptomat
subject
peopl
board
diamond
princess
cruis
ship
test
percentag
asymptomat
subject
ci
coronavirus
envelop
nonseg
positivesens
rna
virus
whose
name
due
clubshap
spike
project
eman
surfac
virion
give
appear
solar
corona
virion
structur
compos
spike
membran
envelop
e
nucleocapsid
n
protein
gain
entranc
lung
cell
thank
interact
protein
angiotensinconvert
enzym
follow
replic
subgenom
rna
synthesi
viral
structur
protein
e
insert
endoplasm
reticulum
er
viral
genom
form
matur
virion
transport
cell
surfac
vesicl
releas
exocytosi
coronavirus
divid
four
genera
alpha
beta
delta
gamma
outbreak
six
coronavirus
belong
either
alpha
beta
group
known
caus
respiratori
diseas
human
four
provok
upper
respiratori
tract
two
strain
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
respons
sever
human
pneumonia
fullgenom
sequenc
reveal
belong
betacoronaviru
diverg
merscov
sarscov
consid
genet
similar
bat
coronaviru
share
genom
hypothesi
origin
bat
like
sarscov
merscov
origin
bat
transmit
human
intermedi
host
analog
author
suggest
pangolin
mink
snake
turtl
may
potenti
intermedi
host
viru
first
vast
major
affect
patient
link
wuhan
seafood
market
suggest
possibl
anim
environment
exposur
soon
howev
persontoperson
spread
report
becam
main
mode
transmiss
asymptomat
presymptomat
patient
transmit
infect
spread
seem
occur
mainli
via
droplet
author
detect
peak
concentr
viru
upper
airway
day
onset
shed
viral
rna
sputum
outlast
end
symptom
far
clinic
impact
infect
pregnanc
concern
current
limit
knowledg
current
evid
vertic
transmiss
third
trimest
manifest
median
incub
period
day
ci
day
rang
day
vast
major
patient
becom
symptomat
day
ci
day
infect
classic
flulik
symptom
initi
includ
fever
dri
cough
fatigu
rhinorrhea
myalgia
less
frequent
headach
diarrhea
infect
progress
affect
lower
respiratori
tract
induc
dyspnea
increas
respiratori
frequenc
decreas
oxygen
satur
respiratori
failur
septic
shock
multiorgan
dysfunct
mani
patient
seem
report
loss
smell
tast
infect
imag
studi
show
patient
bilater
lung
involv
multilob
involv
also
common
multifoc
patchi
bilater
ground
glass
opac
consolid
bronchiectasi
typic
abnorm
observ
comput
tomographi
ct
chest
preferenti
peripher
distribut
lower
lung
involv
laboratori
data
usual
show
lymphopenia
decreas
albumin
high
valu
creactiv
protein
crp
erythrocyt
sediment
rate
esr
lactat
dehydrogenas
significantli
high
circul
level
cytokin
chemokin
note
patient
infect
plasma
concentr
gcsf
higher
icu
patient
nonicu
patient
higher
level
neutrophil
ast
ldh
crp
lower
level
platelet
albumin
describ
refractori
patient
old
age
presenc
underli
diseas
elev
inflammatori
marker
seem
predictor
fatal
outcom
regard
pediatr
age
known
relat
diseas
less
frequent
less
aggress
itali
posit
case
year
age
death
record
year
age
number
collect
chines
center
diseas
control
prevent
reveal
children
age
year
old
repres
case
children
adolesc
age
year
old
confirm
posit
subject
dong
et
al
studi
epidemiolog
characterist
pediatr
patient
suspect
confirm
infect
identifi
januari
februari
china
author
describ
asymptomat
mild
moder
cours
case
patient
total
asymptomat
consid
asymptomat
children
posit
laboratori
test
without
clinic
sign
symptom
radiolog
chest
find
mild
symptom
acut
upper
respiratori
tract
infect
absenc
auscultatori
abnorm
children
digest
symptom
moder
pneumonia
obviou
hypoxemia
spectrum
manifest
observ
pediatr
age
includ
fever
frequent
low
grade
cough
pharyng
erythema
tachycardia
tachypnea
less
usual
rhinorrhea
diarrhea
vomit
fatigu
children
may
show
coinfect
viral
pneumonia
seri
chines
children
eight
show
concomit
infect
influenza
virus
b
respiratori
syncyti
viru
mycoplasma
pneumonia
cytomegaloviru
major
pediatr
patient
normal
blood
count
show
leukocytosi
leukopenia
crp
esr
also
frequent
normal
rang
henc
adult
lymphocyt
platelet
count
crp
albumin
level
propos
sign
sever
infect
children
potenti
prognost
valu
indic
clear
chest
ct
find
document
almost
half
children
appear
similar
milder
compar
found
adult
plain
chest
xray
may
fail
detect
lesion
may
unabl
detail
patholog
featur
final
experi
neonat
motherchild
transplacent
transmiss
limit
pregnant
women
typic
featur
pneumonia
present
nonpregn
women
outcom
neonat
seem
favor
data
obtain
small
group
women
pneumonia
third
trimest
pregnanc
support
intrauterin
infect
caus
vertic
transmiss
patient
juvenil
idiopath
arthriti
prone
infect
especi
period
diseas
activ
top
antirheumat
drug
may
increas
suscept
seriou
infect
common
advers
event
might
relat
biolog
agent
howev
data
larg
epidemiolog
studi
well
nation
registri
reassur
hypothes
exampl
rate
hospit
bacteri
infect
among
patient
diagnos
jia
attent
deficit
hyperact
disord
show
spectrum
infect
compar
group
increas
rate
infect
found
jia
patient
treat
mgday
prednison
use
immunosuppress
risk
infect
studi
particular
attent
tnf
inhibitor
howev
definit
cohort
differ
among
publish
articl
studi
come
british
societi
paediatr
adolesc
rheumatolog
increas
incid
medic
signific
infect
among
patient
treat
etanercept
compar
methotrex
mtx
user
found
ahr
ci
german
biolog
registri
pediatr
rheumatolog
found
increas
risk
sever
infect
either
etanercept
adalimumab
compar
mtx
hazard
ratio
ci
ci
respect
differ
etanercept
adalimumab
know
diseas
activ
predispos
risk
infect
inde
studi
clinic
juvenil
arthriti
diseas
activ
score
found
independ
risk
factor
infect
multivari
analysi
lee
et
al
show
concern
risk
infect
jia
patient
receiv
tnf
inhibitor
identifi
increas
risk
bacteri
infect
requir
hospit
compar
dmard
user
adjust
hazard
ratio
ci
howev
consid
possibl
influenc
previou
mtx
treatment
note
relev
epidem
aforement
studi
respiratori
system
usual
prefer
site
infect
regard
specif
viral
infect
influenza
quit
extens
studi
also
possibl
season
vaccin
among
other
incid
herp
zoster
viru
infect
found
almost
threefold
higher
jia
patient
also
despit
earli
vaccin
possibl
hepat
b
viru
reactiv
antitnf
treatment
report
incid
among
patient
jia
yet
unknown
experi
far
short
make
conclus
statement
awar
larg
cohort
chloroquin
cq
hydroxychloroquin
hcq
use
antimalari
drug
decad
furthermor
thank
immunomodulatori
properti
hcq
current
use
manag
autoimmun
diseas
sle
ra
studi
demonstr
drug
vitro
abl
interfer
differ
virus
vitro
cq
decreas
glycosyl
hinder
entranc
viru
host
cell
furthermor
cq
hcq
increas
ph
endosom
cell
prevent
fusion
process
host
viral
membran
hcq
therapi
may
use
infect
antivir
activ
abil
decreas
cytokin
product
suppress
tlr
signal
decreas
interferon
pathway
activ
may
dampen
inflammatori
phase
diseas
final
hcq
also
proven
efficaci
prevent
recurr
acut
respiratori
distress
syndrom
children
interstiti
lung
diseas
due
monogen
surfact
defici
least
differ
trial
ongo
china
six
other
regist
test
efficaci
cq
hcq
treatment
preliminari
result
gautret
et
al
suggest
hcq
mg
daili
may
decreas
viral
load
nasal
swab
furthermor
gao
report
chloroquin
phosphat
superior
control
treatment
inhibit
exacerb
pneumonia
improv
lung
imag
find
promot
viru
neg
convers
shorten
diseas
cours
recent
report
yao
et
al
demonstr
pharmacokinet
model
vitro
hcq
potent
cq
accord
studi
load
dose
mg
twice
daili
hcq
given
oral
follow
mainten
dose
mg
given
twice
daili
day
therapeut
regimen
recommend
critic
ill
patient
admit
intens
care
unit
icu
care
fatal
outcom
significantli
higher
cytokin
level
compar
patient
milder
diseas
suggest
cytokin
storm
may
play
role
covid
mortal
particular
zhou
et
al
demonstr
retrospect
studi
survivor
significantli
lower
level
nonsurvivor
preliminari
result
tocilizumab
tcz
use
provid
xu
et
al
report
mark
improv
patient
treat
tcz
term
decreas
need
decreas
inflammatori
marker
resolut
ct
lesion
base
upon
find
singl
arm
phase
studi
also
approv
italian
regulatori
drug
agenc
enrol
patient
pneumonia
earli
respiratori
failur
mortal
reduct
month
primari
outcom
eudract
number
particip
receiv
dose
tcz
mgkg
second
dose
could
given
h
respiratori
function
recov
us
anoth
phase
trial
blocker
sarilumab
current
ongo
import
cytokin
storm
pneumonia
may
suggest
cytokin
blocker
may
benefici
treatment
sever
case
interestingli
biomark
diseas
progress
resembl
well
known
marker
macrophag
activ
syndrom
high
ferritin
low
platelet
high
alt
consid
similar
treatment
blocker
may
benefici
phase
random
openlabel
multicent
studi
investig
efficaci
safeti
emapalumab
anakinra
versu
standard
care
reduc
hyperinflamm
respiratori
distress
patient
infect
current
ongo
eudract
number
march
franc
health
author
deliv
warn
regard
use
nsaid
patient
affect
due
possibl
sever
side
effect
march
ema
declar
current
scientif
evid
establish
link
ibuprofen
worsen
ema
recommend
start
treatment
fever
pain
patient
health
care
profession
consid
avail
treatment
option
includ
paracetamol
nsaid
medicin
benefit
risk
reflect
product
inform
consid
along
eu
nation
treatment
guidelin
recommend
paracetamol
first
treatment
option
fever
pain
evid
regard
possibl
side
effect
nsaid
lack
suggest
indomethacin
nsaid
use
system
jia
potent
antivir
activ
coronaviru
pediatr
rheumatologist
daili
confront
patient
famili
request
inform
proceed
regard
schedul
appoint
infus
visit
well
ask
whether
chang
therapi
advis
due
possibl
increas
risk
suscept
infect
secondari
immunosuppress
treatment
particular
corticosteroid
biolog
scientif
societi
italian
societi
rheumatolog
pediatr
rheumatolog
european
societi
european
leagu
rheumat
issu
recommend
easili
download
web
site
obvious
follow
statement
well
advis
famili
follow
individu
countri
ministri
healthnat
public
health
care
bodi
recommend
adult
rheumatolog
depart
issu
relev
statement
relat
rheumatoid
arthriti
center
alway
underlin
simpl
measur
prevent
contact
infect
subject
spread
viru
ie
often
clean
hand
soap
alcoholbas
sanit
avoid
contact
peopl
manifest
respiratori
symptom
keep
safe
social
distanc
least
one
meter
cough
sneez
palm
elbow
use
dispos
tissu
tell
patient
famili
avoid
touch
face
much
possibl
emerg
depart
visit
avoid
unless
strictli
necessari
primari
care
physician
pediatrician
contact
case
fever
respiratori
symptom
outpati
consult
elect
hospit
defer
oncal
number
answer
specif
question
creat
center
use
especi
patient
miss
appoint
moment
recommend
rheumatolog
societi
itali
europ
suggest
continu
immunosuppress
therapi
usual
sinc
medic
withdraw
may
caus
flare
inflammatori
diseas
turn
lead
higher
infecti
risk
regard
drug
deliveri
hospitalprescrib
medic
sever
prescript
itali
automat
renew
day
present
time
swab
prescrib
asymptomat
individu
screen
health
care
provid
discuss
ie
next
import
peopl
protect
sinc
everyday
contact
allow
definit
physician
asymptomat
peopl
could
theoret
carri
viru
potenti
contagi
sourc
danger
spread
children
famili
contact
particular
elderli
subject
risk
sever
cours
diseas
therefor
use
person
protect
equip
depend
specif
clinic
situat
requir
epidem
pandem
may
affect
million
peopl
worldwid
time
children
seem
spare
least
sever
consequ
infect
physician
deal
patient
chronic
diseas
particular
immunosuppress
subject
awar
possibl
risk
link
drug
use
treat
rheumatolog
disord
howev
hint
drug
might
benefici
fight
infect
use
social
isol
hygien
measur
fundament
order
decreas
viral
spread
